

ENANNEX

Point 8.3. of Annex VII shall be replaced by the following:

<p>"8.3. Skin sensitisation Information allowing</p> <ul style="list-style-type: none"> - a conclusion whether the substance is a skin sensitiser and whether it can be presumed to have the potential to produce significant sensitisation in humans (Cat. 1A), and - risk assessment, where required 	<p>The study(ies) under point 8.3.1. and 8.3.2. do not need to be conducted if:</p> <ul style="list-style-type: none"> — the substance is classified as skin corrosion (Category 1), or — the substance is a strong acid ($\text{pH} \leq 2,0$) or base ($\text{pH} \geq 11,5$), or — the substance is spontaneously flammable in air or in contact with water or moisture at room temperature.
<p>8.3.1. Skin sensitisation, <i>in vitro/in chemico</i></p> <p>Information from <i>in vitro/in chemico</i> test method(s) recognised according to article 13(3), addressing each of the following key events of skin sensitisation</p> <ul style="list-style-type: none"> (a) Molecular interaction with skin proteins (b) Inflammatory response in keratinocytes (c) Activation of dendritic cells 	<p>The(se) test(s) do not need to be conducted if</p> <ul style="list-style-type: none"> - an <i>in vivo</i> study according to point 8.3.2. is available, or - the available <i>in vitro/in chemico</i> test methods are not applicable for the substance or are not adequate for classification and risk assessment according to point 8.3. <p>If information from test method(s) addressing one or two of the key events in column 1 already allows classification and risk assessment according to point 8.3, studies addressing the other key event(s) need not to be conducted.</p>
<p>8.3.2. Skin sensitisation, <i>in vivo</i>.</p>	<p>An <i>in-vivo</i> study shall be conducted only if <i>in vitro/in chemico</i> test methods described under point 8.3.1. are not applicable, or the results obtained from those studies are not adequate for classification and risk assessment according to point 8.3.</p> <p>The Murine Local Lymph Node Assay (LLNA) is the first-choice method for <i>in vivo</i> testing. Only in exceptional circumstances should another test be used. Justification for</p>

	<p>the use of another <i>in vivo</i> test shall be provided.</p> <p>In-vivo skin sensitisation studies that were carried out or initiated before [date of entry into force], and that meet the requirements set out in Article 13(3), first subparagraph, and Article 13(4) shall be considered appropriate to address this standard information requirement."</p>
--	--